Rein Therapeutics, Inc. Common Stock RNTX Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $0— | $0— | $0— | $0— | $0— | ||
| $11.05M+0.2% | $11.03M-10.7% | $12.35M-14.2% | $14.39M+4.0% | $13.84M-2.9% | ||
| $10.51M-3.7% | $10.9M-4.5% | $11.42M+14.7% | $9.96M-21.4% | $12.68M-8.6% | ||
| $50.25M-0.7% | $50.63M-16.7% | $60.77M-0.9% | $61.35M-3.4% | $63.52M-2.5% | ||
| -$50.25M+0.7% | -$50.63M+16.7% | -$60.77M+0.9% | -$61.35M+3.4% | -$63.52M+2.5% | ||
| —— | —— | $340K-47.9% | $653K-6.8% | $701K+2.3% | ||
| —— | -$712K+22.6% | -$920K+18.4% | -$1.13M+15.6% | -$1.34M+13.5% | ||
| -$50.21M-0.7% | -$49.87M+15.3% | -$58.89M+0.4% | -$59.15M+3.5% | -$61.27M+2.6% | ||
| -$1.90+3.1% | -$1.96+33.3% | -$2.94+2.0% | -$3.00+5.4% | -$3.17+16.1% | ||
| -$50.25M+0.7% | -$50.63M+16.7% | -$60.77M+0.9% | -$61.35M+3.4% | -$63.52M+2.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Rein Therapeutics, Inc. Common Stock profitable?
- Rein Therapeutics, Inc. Common Stock is not currently profitable: it reported a net loss of $50.2M over the trailing twelve months.
- What is Rein Therapeutics, Inc. Common Stock's earnings per share?
- Rein Therapeutics, Inc. Common Stock's diluted EPS over the trailing twelve months is $-1.90.
- Where does Rein Therapeutics, Inc. Common Stock's income statement data come from?
- Every line is extracted from Rein Therapeutics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.